26H Stock Overview
A neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Helius Medical Technologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.12 |
| 52 Week High | US$10.80 |
| 52 Week Low | US$1.12 |
| Beta | 1.59 |
| 11 Month Change | -7.44% |
| 3 Month Change | -80.18% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -83.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| 26H | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -2.6% | -3.5% | 0.8% |
| 1Y | n/a | 2.2% | 6.1% |
Return vs Industry: Insufficient data to determine how 26H performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how 26H performed against the German Market.
Price Volatility
| 26H volatility | |
|---|---|
| 26H Average Weekly Movement | 14.7% |
| Medical Equipment Industry Average Movement | 4.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 26H's share price has been volatile over the past 3 months.
Volatility Over Time: 26H's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 22 | Dane Andreeff | heliusmedical.com |
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company’s product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. Helius Medical Technologies, Inc. was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.
Helius Medical Technologies, Inc. Fundamentals Summary
| 26H fundamental statistics | |
|---|---|
| Market cap | €2.58m |
| Earnings (TTM) | -€8.20m |
| Revenue (TTM) | €617.77k |
4.2x
P/S Ratio-0.3x
P/E RatioIs 26H overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 26H income statement (TTM) | |
|---|---|
| Revenue | US$668.00k |
| Cost of Revenue | US$584.00k |
| Gross Profit | US$84.00k |
| Other Expenses | US$8.96m |
| Earnings | -US$8.87m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.99 |
| Gross Margin | 12.57% |
| Net Profit Margin | -1,328.14% |
| Debt/Equity Ratio | 0% |
How did 26H perform over the long term?
See historical performance and comparison